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Abstract The long-lasting persistence of hepatitis B virus
(HBV) genomes in the liver (with detectable or undetectable
HBV DNA in the serum) of individuals testing negative for
the HBV surface antigen (HBsAg) is termed occult HBV
infection (OBI). Although in a minority of cases the lack of
HBsAg detection is due to infection with variant viruses
unrecognized by available assays (S-escape mutants), the
typical OBI is related to replication-competent HBVs strongly
suppressed in their replication activity. The causes of HBV
suppression are not yet well clarified, although the host’s
immune surveillance and epigenetic mechanisms are likely
involved. OBI is a worldwide diffused entity, but the available
data of prevalence in various categories of individuals are
often contrasting because of the different sensitivity and spec-
ificity of the methods used for its detection in many studies.
OBI may have an impact in several different clinical contexts.
In fact, it can be transmitted (i.e., through blood transfusion
and liver transplantation) causing classic forms of hepatitis B
in newly infected individuals. The development of an immu-
nosuppressive status (mainly by immunotherapy or chemo-
therapy) may induce OBI reactivation and development of
acute and often severe hepatitis. Finally, evidence suggests
that OBI can favor the progression of liver fibrosis, in partic-
ular in HCV-infected patients. The possible contribution of
OBI to the establishment of cirrhosis also implies its possible
indirect role in the development of hepatocellular carcinoma.
On the other hand, OBI may maintain most of the direct
transforming properties of the overt HBV infection, such as
the capacity to integrate in the host’s genome and to synthesize
pro-oncogenic proteins.
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HBVoncogenecity
According to European guidelines on management of chronic
hepatitis B (CHB) virus (HBV) infection, the natural history
of CHB can be schematically divided into five—not neces-
sarily sequential and stable—phases [1], the fifth of which is
occult HBV infection (OBI) that a panel of experts recently
defined as the presence of viral DNA in the liver (with
detectable or undetectable HBV DNA in the serum) of indi-
viduals testing negative for the HBV surface antigen (HBsAg)
[2]. Suspected to exist since the 70s and the occasional topic
of a few important studies for more than two decades, general
interest in OBI arose and became a major issue of hepatology
research from 1999 when The New England Journal of Med-
icine published a study performed by testing the liver biopsy
specimens from a large series of HBsAg-negative patients
with chronic liver disease (CLD) for HBV genomes [3]. In
fact, this study provided new insight in both the virological
aspects and the possible clinical implications of OBI showing
that (a) it may favor or accelerate the progression toward
cirrhosis of hepatitis C virus (HCV)-related chronic hepatitis
and that (b) “occult” viruses usually have no genetic mutations
capable of preventing viral replication as well as HBsAg
synthesis (Table 1). As a consequence of the growing interest
in OBI that followed the publication of this paper [2–15], we
are observing a considerable, continuous increase of the
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number of studies in this field published by journals covering
different areas of biomedical interest (Fig. 1). In this review,
we aimed at revising the collection of data on OBI, also
stressing the aspects that are largely accepted by the scientific
community and those that are still debated.
Virology
HBV belongs to the Hepadnaviridae family, comprising
hepatotropic DNA viruses able to infect mammalian and
avian hosts and sharing with HBV most of the genetic
structure and replicative characteristics [16]. HBV genome
consists of a partially double-stranded relaxed circular
DNA, approximately 3,200 nucleotides in length, and con-
tains four partially overlapping open-reading frames (ORF),
pre-S/S, pre-C-C, P, and X. Pre-S/S ORF, which encode the
three viral surface proteins, preS1 (or Large), preS2 (or Mid-
dle), and S (or small), which correspond to HBsAg. PreC/C
ORF encodes the core antigen (HBcAg) and the soluble
antigen “e” (HBeAg). P ORF encodes the terminal protein
(TP) and the viral polymerase that possesses DNA polymer-
ase, reverse transcriptase, and RNaseH activities. X ORF
encodes the regulatory X protein, which is essential for virus
replication and is capable of transactivating the expression of
numerous cellular and viral genes [17].
The replication cycle of HBV presents very particular
characteristics that can be schematically summarized as
follows [17]: (a) interaction of the virus with still unidenti-
fied cell surface receptors; (b) release of the core nucleo-
capsid into the cytoplasm and its transport to the nuclear
membrane; (c) discharge of the HBV genome into the nu-
cleus and its conversion into a covalently closed circular
DNA (cccDNA); (d) transcription of cccDNA by the host
Table 1 Milestones in the progression of knowledge of occult HBV infection
Year—journal—authors Topic
1975—Gastroenterology—Wands et al. [4] OBI reactivation in patients undergoing chemotherapy
1978—N Engl J Med—Hoofnagle et al. [13] HBV transmission by blood transfusion from an OBI donor
1981—N Engl J Med—Shafritz et al. [7] HBV DNA integration in the hepatocyte genome of HBsAg-negative individuals
1981—Proc Natl Acad Sci—Brechot et al. [15]
1988—Lancet—Thiers et al. [6] Acute hepatitis B in chimpanzees injected with HBV isolates from blood of OBI carriers
1989—Proc Natl Acad Sci—Kaneko et al. [12] Polymerase chain reaction detection of HBV DNA in serum of HBsAg-negative individuals
1994—Lancet—Chazouillères et al. [14] Liver transplant from OBI donors may induce hepatitis B in recipients
1994—J Clin Invest—Michalak et al. [11] OBI in patients recovered from acute hepatitis B
1996—Nature Medicine—Rehermann et al. [8] A strong CTL-specific anti-HBV response persists over time in patients
who recovered from acute hepatitis B1996—J Clin Invest—Penna et al. [10]
1999—N Engl J Med—Cacciola et al. [3] OBI is associated with cirrhosis in patients with chronic hepatitis C and the virus is wild-type
2002—Lancet Inf Dis—Torbenson and Thomas [5] First systematic review of the OBI field
2004—Gastroenterology—Pollicino et al. [9] Molecular analyses of a large series of liver tumor tissues confirm
the association between OBI and HCC
2008—J Hepatol—Raimondo et al. [2] Statements on OBI by an international, large panel of experts
Fig. 1 Publications on
occult HBV infection
over time
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RNA polymerase II into all viral mRNA, including a pre-
genomic RNA (pgRNA); (e) translocation of HBV tran-
scripts into the cytoplasm, where their translation yields
the viral envelope, core, “e”, polymerase, and X proteins;
(f) assembly of nucleocapsids and, inside them, synthesis of
new viral DNA from pgRNA by viral reverse transcriptase;
(g) recycling of a small portion of nucleocapsids into the
nucleus to maintain the reservoir of cccDNA stable; and (h)
coating of most nucleocapsids with viral surface proteins in
the endoplasmic reticulum and subsequent release of mature
virions. HBV has been classified as a pararetrovirus because
of some similarity with retroviruses. In fact, HBV—although
a DNA virus—replicates through the reverse transcription of
the pgRNA representing its intermediate replicative form.
Similar to retroviruses, HBV DNA can integrate in the ge-
nome of the host hepatic cells but, unlike what happens for
retroviruses, integration has no role in the replicative cycle of
HBV and it involves only segments of the viral genome.
Integrated HBV may persist forever in the liver cells of
infected individuals even when they are HBsAg-negative.
However, the presence of integrated viral DNA in HBsAg-
negative subjects should not be strictly considered as occult
infection, since this condition is essentially related to the
intrahepatic long-lasting persistence of entire viral genomes
as free episomal forms and, in particular, to the persistence of
viral cccDNA, as a stable chromatinized episome, in the
nucleus of the infected cells [18]. The stability and long-
term persistence of viral cccDNA molecules together with
the long half-life of hepatocytes imply that HBV infection,
once it has occurred, may continue indefinitely over time
[18, 19].
The lack of detectable HBsAg in spite of the presence of
episomal, free HBV genomes at intrahepatic level is attribut-
able, in some cases, to the HBV genetic variability determin-
ing either infection with S gene variants (S-escape mutants)
producing a modified HBsAg that is not recognized by com-
mercially available detection kits (even when the most sensi-
tive ones are used) or, in a small number of cases, infection
with HBV mutants with defective replication activity or syn-
thesis of S proteins [20]. However, in the majority of cases,
“occult” HBV genomes are replication-competent viruses
with grade and relevance of genetic heterogeneity comparable
with the HBV isolates from individuals with “overt” (HBsAg-
positive) infection [21]. Thus, it is generally believed that the
OBI status is mostly consequent to a strong suppression of
HBV replication and gene expression where different mecha-
nisms can be implied. Before discussing these mechanisms, it
is important to consider that although OBI is significantly
associated with the presence of anti-HBVantibodies (namely,
anti-HBc and anti-HBs antibodies directed against the viral
core antigen and HBsAg, respectively), more than 20 % of
occult-infected individuals are negative for all HBV serum
markers [5]. Consequently, and according to the above-
mentioned Taormina statements, one can distinguish seropos-
itive (anti-HBc and/or anti-HBs positive) and seronegative
OBI (anti-HBc and anti-HBs negative) individuals. In sero-
positive OBI, the HBsAgmay become negative either quickly
after the resolution of acute hepatitis or after years or decades
of overt chronic HBVinfection, whereas the seronegative OBI
cases might have either progressively lost all HBV serum
markers or might be HBV-negative since the beginning of
the infection, similarly to what was observed in the wood-
chuck model of hepadnavirus infection with the woodchuck
hepatitis virus (WHV) [22] (Fig. 2). Thus, OBI appears to
shape up as a complex scenario with different virological and
immunological profiles.
Mechanisms potentially involved in HBV inhibition
and OBI status induction
The experimental systems available at present are not suit-
able for an adequate study of HBV infection, which is a
complex event characterized by different and often instable
phases [1]. Thus, knowledge of the factors implicated in
suppression of the viral activity up to the induction of occult
HBV status is still very limited. Nevertheless, it would be of
utmost importance to define these factors, since their eluci-
dation would reveal important insights into HBV virology
and provide information for new therapeutic strategies fitted.
Below we will discuss data and hypotheses concerning host
factors that are generally believed to be involved in the sup-
pression of HBV replication and in control of the infection.
Finally, we will alsomention the possible role that viral factors
and coinfection with other viral and nonviral agents may play
in inducing OBI status.
Host factors
Much evidence indicates that host factors are strongly im-
plicated in the induction and maintenance of the occult
status of HBV infection. Further proof is provided by a
recent in vitro study showing that replication, transcription,
and protein synthesis abilities of occult viral isolates can be
fully restored once the viruses are taken out from the host’s
liver microenvironment [21].
Immunological factors
Numerous clinical studies have clearly demonstrated since
the 70s that all the conditions inducing immunosuppression
(i.e., hematologic malignancies, chemo- or immunothera-
pies, etc.) may provoke the reactivation of OBI with the
reappearance of the typical serological profile of overt active
infection [4, 5, 20]. This is quite strong (though indirect)
evidence of the involvement of the host’s immune
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surveillance in the OBI development. This involvement is also
confirmed by the data showing that a long-lasting memory
CD4 and CD8 cell responses against HBV antigens are still
detectable several years after recovery from acute hepatitis B
possibly because during the occult phase of the infection,
HBV is still able to synthesize minute amounts of antigens,
which are undetectable by available technical approaches but
are sufficient enough to maintain an HBV-specific T cell
response [8, 10]. Indeed, besides HBV cccDNA molecules,
all viral transcripts have been detected in the liver of occult-
infected individuals [9, 23, 24] and real-time PCR quantifica-
tion has revealed small but still quantifiable amounts of intra-
hepatic HBVmRNA in these subjects [24]. Therefore, clinical
recovery from HBV infection not only implies the lack of
complete clearance of the virus but also reflects the ability of
the immune system to keep under tight control leftover viruses
in the liver after clinical resolution of disease.
In a recent study, Zerbini et al. demonstrated that OBI
patients with and without anti-HBc antibodies displayed a
different profile of HBV-specific T cell responses [25].
Indeed, although circulating HBV-specific T cells were
detected in seronegative (anti-HBc negative) patients with
occult infection at frequencies comparable with seropositive
(anti-HBc positive) OBI subjects, in vitro expansion and
IFN-γ production by HBV-specific T cells was much weaker
than in OBI-seropositive individuals. On the basis of the
evidence obtained in the woodchuck animal model, it has
been hypothesized that these distinct behaviors of cell-
mediated immune responses in seropositive and seronegative
OBIs might reflect different modalities of HBV transmission
[22]. Indeed, in the woodchuck model, exposure to lowWHV
doses (<103 virions) may give rise to a persistent infection in
the absence of viral serum markers. Interestingly, this so-
called woodchuck “primary” occult infection does not confer
protective immunity, suggesting that a functional memory T
cell response is generated only after infection with a higher
dose of inoculum [22].
A very recent study has largely confirmed the observa-
tions of Zerbini et al. by investigating HBV-specific immune
responses in blood donors with OBI [26]. In these subjects,
potent, multispecific HBV-specific T cell responses were
observed. In particular, HBV-specific Th1 responses were
quantitatively stronger in OBI than in inactive carriers and
were similar or even higher against HBVantigens than those
observed in patients with previous HBV resolution. These
data led the authors to conclude that the host’s immune
system has the ability to strongly suppress HBV replication,
thus providing a plausible explanation to the very low (or even
absent) viral loads and the lack of detectable HBsAg observed
in OBI individuals [26].
Other relevant evidence on the importance of the host’s
immune systems in OBI control derives from studies on
HIV-infected patients [27]. It has been recently shown that
in these patients HBV viremia, in cases of occult infection, is
significantly associated with lower CD4 counts. In patients
with CD4 counts >500 cells/mm3, no occult HBV was ob-
served. Thus, cellular immune deficiency, as reflected by the
reduced CD4 counts in HIV infection, might result in a de-
creased control of HBV activities, so that HBV can restart to
replicate and become detectable.
Of interest, the study of cytokine expression in HIV-
infected individuals has shown decreased levels of IL-8,
IL-10, IP-10, sFas, and sFasL in OBI patients compared to
patients with overt HBV infection [28]. In particular, sFas
levels were significantly reduced during occult infection,
suggesting a reduced inhibition of apoptosis in this
Fig. 2 Schematic
representation of the various
conditions leading to different
OBI serological profiles
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condition which, in turn, could favor a partial viral clearance,
thus contributing to OBI occurrence [28].
Several relevant data suggest that not only the adaptive
but also the innate immune response may play a role in the
control of viral replication. Experiments with HBV-replicating
transgenic mice and chimpanzees have shown that inflamma-
tory cytokines, such as interferon type 1 (IFN) and TNF-α,
can efficiently suppress viral replication through noncytolytic,
immune-mediated mechanisms [29]. Moreover, it was more
recently demonstrated that liver cells can mount an effective
innate response to HBV infection with the production of
INF-β- and IFN1-stimulated genes, which, in turn, may
control HBV replication [30]. Thus, one might speculate
that innate immune response might be implicated in con-
trolling HBV activities, particularly in seronegative OBI
patients in whom poor in vitro T cell expansion has been
observed.
Epigenetic factors
HBV cccDNAmolecules accumulate in the nucleus of infected
hepatocytes as stable minichromosomes packaged into nucleo-
somal arrays by histone and nonhistone proteins, similarly to
host cell chromatin [18]. Nucleosomal organization of viral
genomes has been described for several DNA viruses such as
the polyoma viruses, herpesviruses, simian virus 40, and hu-
man and bovine papilloma viruses [31]. A number of recent
discoveries have underscored the importance of chromatin
dynamic changes in histone composition and modification in
tthe regulation of gene expression and replication during the
different stages of viral productive replication, latent infection,
and reactivation from latency, heightening the possibility that
epigenetic processes may dictate, at least in part, the outcome of
infection [31]. Both Epstein–Barr virus (EBV) and herpes
viruses (HHV), for example, make extensive use of epigenetic
modifications of histones as a mechanism of transcriptional
control during their latency status [32, 33].
We have recently developed a ChIP-based HBV cccDNA
quantitative approach to study the recruitment in vivo of
cellular and viral proteins onto the HBV minichromosome
[34]. The HBV cccDNA ChIP assay couples a cccDNA
ChIP technique with a sensitive and specific real-time
PCR protocol for cccDNA quantification [18, 34, 35]. Using
the cccDNA-ChIP assay, we were able to show that HBV
genomes are targeted by epigenetic regulatory mechanisms.
Firstly, we could confirm existing data concerning the re-
cruitment, in vivo, of H3/H4 histones and of HBV core
protein on the cccDNA minichromosome [34]. Subsequent-
ly, using the same approach, we and others showed that
several cellular transcription factors, including CREB,
ATF, STAT1, and STAT2, and different chromatin modify-
ing enzymes can bind the cccDNA in cells replicating HBV
[36, 37]. Indeed, using antiacetylated-H3 or antiacetylated-
H4 cccDNA ChIP assay, we found that HBV replication is
regulated, both in cell-based replication systems and in the
liver of HBV chronically infected patients, by the acetyla-
tion status of H3/H4 histones bound to the viral cccDNA in
the nuclei of HBV-infected hepatocytes. The corecruitment
of histone acetyltransferases (PCAF and p300/CBP) paral-
leled viral replication in vitro, whereas histone deacetylase 1
(HDAC1) recruitment onto the cccDNAwas correlated with
low HBV replication in vitro and with low viremia in vivo
[34]. The importance of cccDNA histone epigenetic mod-
ifications in the regulation of the viral transcription/replica-
tion is further confirmed by the observation that abrogation
of PCAF expression by specific siRNAs reduces HBV rep-
lication and acetylation of cccDNA-bound histones, where-
as the class I and class III histone deacetylase inhibitors
trichostatin, valproate, and nicotinamide induce an evident
increase of both cccDNA-bound acetylated H4 and HBV
replication. Interestingly, valproate, which is used clinically
as an anticonvulsant and in the treatment of bipolar syn-
dromes, has been shown to reactivate lytic replication both
of latent HHV8 and of EBV [38, 39]. As a note, a fatal
reactivation of hepatitis B has been described in a 65-year-
old Chinese woman who received radiation therapy with
concurrent temozolomide because of a glioblastoma and
valproic acid for seizure prophylaxis [40].
Preliminary data, obtained by applying the ChIP assay to
liver tissues of patients with OBI, showed that in these sub-
jects cccDNA-bound histones were hypoacetylated and the
recruitment of chromatin-silencing factors as HDAC1, the
heterochromatin proteins HP1, and the histone H3 K9 meth-
ylase SUV39H1 were increased. Thus, the profound suppres-
sion of transcription/replication of the occult HBVepisome in
OBI livers might occur at the level of chromatin organization
(Pollicino et al, unpublished data).
Interestingly, recent evidence indicates that IFNα is able to
inhibit cccDNA-driven transcription of genomic and subge-
nomic RNAs, both in HBV-replicating cells and in HBV-
infected chimeric uPA/SCID mice repopulated with primary
human hepatocytes. In particular, it was found that, in response
to IFNα, cccDNA-bound histones become hypoacetylated and
both components of the transcriptional repressor complex
PRC2 are actively recruited on the cccDNA [41]. These obser-
vations support the hypothesis that the ability of IFNα to inhibit
HBV replication may be mediated, also by an active epigenetic
control of HBV minichromosome. In addition to post-
translational modifications of histones, DNA methylation of
CpG-rich regions (CpG islands) in the HBV DNA might also
contribute to regulate HBV gene expression. [18, 42, 43].
Viral factors
Since the lack of detectable HBsAg in serum is a characteriz-
ing feature of OBI, considerable interest has been focused on
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mutations in the surface gene and its regulatory regions. Thus,
besides mutation clustering in key immunodominant regions
of the surface protein able to decrease the immune recognition
of the virus, deletions in the preS1 region impairing viral
packaging, structural alteration in genomic regulatory regions
leading to a strong reduction of HBsAg expression, and muta-
tions affecting posttranslational production of HBV proteins
have been described [2, 20, 44].
As stressed above, however, most of the studies have
shown that these mutations are not detected in HBV isolates
from the great majority of occult HBV-infected individuals
and importantly, they are not unique to occult HBV but can be
found in isolates from patients with overt HBV infections,
including those with high viral loads [21, 26, 45, 46].
Coinfection
HBV activity might be impaired by other infectious agents
in cases with coinfection. In particular, HCV has been
suspected to strongly suppress HBV replication up to the
point where it determines OBI development in coinfected
individuals. In fact, a number of in vitro studies had clearly
demonstrated that the HCV “core” protein strongly inhibits
HBV replication [47] and OBI shows the highest prevalence
precisely in HCV-infected patients [5, 20]. However, more
recent studies have brought into question the interplay be-
tween HCV and HBV, and when the in vitro cotransfection
experiments were conducted with full-length HBV genomes
and HCV replicon (thus, not limiting the study to a single
HCV protein), no interference between the two viruses was
noted [48]. Summarizing, the available data cannot allow
definitive conclusion for any role of HCV in inducing OBI.
Even individuals positive for human immunodeficiency vi-
rus (HIV) frequently show either overt or occult HBV
coinfection, but there is no evidence of possible direct
effects of HIV on HBV activity. Finally, other infectious
agents might also potentially inhibit HBV and it has been
shown that schistosoma mansoni is capable of strongly
suppressing HBV replication in a transgenic mice model
[49].
Detection
Standardized, valid assays for occult HBV detection are not
yet available. According to the above-mentioned Taormina
statements, the gold standard for OBI testing is the analysis
of DNA extracts from liver tissues performed by the use of
highly sensitive and specific techniques, i.e., nested poly-
merase chain reaction (PCR) or real-time PCR, and of
oligonucleotide primers specific for different HBV genomic
regions and complementary to highly conserved (genotype
shared) nucleotide sequences [2]. However, liver tissue
specimens are available only in a minority of the cases,
since needle liver biopsy cannot be performed in most sub-
jects. Thus, the analysis of serum or plasma samples is the
most common approach to identify occult HBV-infected
cases. In this context, to improve the sensitivity of the test
performing DNA extraction from at least 1 ml of serum (or
plasma) and serially testing collected samples has been
suggested in consideration of the fluctuating profile that
detectable viremia often presents in OBI patients [2]. If
highly sensitive HBV DNA testing is not feasible, the sero-
logical assay for anti-HBc antibody should be used as a
possible surrogate marker for identifying potential seropos-
itive OBI individuals in cases of blood, tissue, or organ
donation and when immune suppressive therapy has to be
used. In this context, it must be stressed that not all anti-
HBc positive individuals are found to be HBV DNA-positive
and that anti-HBc tests may provide false positive results
[2, 50, 51].
Prevalence
Considering the HBV life cycle with a long-lasting persis-
tence of viral genomes in most infected patients indepen-
dently of HBsAg status, OBI is expected to be a worldwide
diffused entity, which prevalence is higher in populations at
high risk of parenterally transmitted infections and generally
dependent on the level of HBV endemicity in the different
geographic areas. In addition, there is considerable evidence
indicating that OBI is highly prevalent also in individuals
with CLD and, in particular, in HCV chronically infected
patients [5, 20]. In fact, HBV DNA is detectable in about
one-third of HBsAg-negative HCV carriers in the Mediter-
ranean Basin and in more than 50 % in Far East Asian
countries [5]. Of note, recent studies conducted in the
USA on patients of Caucasian origin undergoing liver trans-
plantation for HCV-related cirrhosis showed that 50 % of
these individuals were OBI-positive [52]. These data are
particularly surprising and relevant taking into account that
HBV prevalence in the Caucasian American population is
one of the lowest in the world [53]. OBI has been less
investigated in patients with HCV-negative CLD. Its preva-
lence has been reported to range between 20 % and 30 % in
subjects with cryptogenic liver disease [5, 20, 23]. In one
study, 12.2 % of patients with chronic hepatitis related to
autoimmune disorders proved OBI-positive when serum sam-
ples were tested, although this prevalence appeared to signif-
icantly increase when viral DNA was also assayed on liver
extracts of a number of those patients [54].
Populations at high risk of parenterally transmitted infec-
tions have been widely investigated for occult HBV. A high
prevalence has been reported in intravenous drug addicts in
Baltimore (45 %) [55] and in hemophiliacs in Japan (51 %)
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[56]. Studies on hemodialysis patients have provided widely
divergent results that cannot be explained solely with the
level of HBVendemicity in different areas [20]. In fact, even
some studies carried out within the same country reported
contradictory data [57–60], thus suggesting that the differ-
ences in sensitivity and/or specificity of the methods used in
the various studies could be the main cause responsible for
the discrepant findings. Of course, since liver biopsy cannot
be routinely performed in hemodialysis patients, no study
evaluating this setting of patients carried out the analysis of
occult HBV on liver specimens. Furthermore, no study
longitudinally evaluated the presence of viral DNA in seri-
ally collected serum samples. Thus, we might suppose that
OBI prevalence is generally underestimated in this subset of
patients. Even more evident is the divergence among the
numerous reports concerning OBI prevalence in HIV-
infected patients [20]. Of note, the highest prevalence was
found when the most sensitive techniques for OBI detection
were used and when longitudinally collected multiple pa-
tient sera were tested. However, only one study evaluated
the presence of HBV sequences at intrahepatic level, show-
ing that 41 % of HIV/HCV coinfected Italian patients also
carried OBI [61]. OBI has been extensively explored in
blood donors where it appears to occur quite rarely in the
western world, whereas it is frequently detected in develop-
ing countries [20]. On the contrary, OBI has been much less
investigated in the general population so far. In a study
evaluating HBsAg-negative residents of a Canadian Inuit
community, HBV DNA was detected in 18 % of anti-HBc
positive subjects and in 8 % of HBV seronegative individ-
uals, respectively [62], whereas occult HBV genomes were
found in 16 % of Korean HBV/HCV-negative healthy sub-
jects with normal transaminase values and in 15.3 % of
healthy hematopoietic stem cell donors from Hong Kong
[63, 64]. We recently investigated the presence of HBV
DNA at intrahepatic level in 98 liver disease-free HBsAg-
negative Italian individuals who underwent liver resection or
needle liver biopsy during abdominal surgery: 16 of them
(16 %) were OBI positive, most having circulating anti-HBV
antibodies [65].
Clinical implication
The great interest in OBI is mainly related to the growing,
widely debated evidence of its clinical impact. Actually,
OBI may be involved in several different clinical contexts
that we schematically group as follows: transmission of the
“occult” virus (mainly through blood transfusion and ortho-
topic liver transplantation, OLT) with consequent hepatitis B
in the recipient; reactivation of the infection and consequent
(re)development of the HBV-related liver disease; effect
on occurrence and progression of the CLD; and role in
hepatocarcinogenesis. Here, we schematically discuss these
different clinical contexts of OBI involvement and cite
recent reports which have suggested a possible involvement
of OBI also in malignancies other than HCC.
Risk of OBI transmission
Blood transfusion
It is well established that carriers of occult infection may be a
source of HBV transmission in the case of blood transfusion
with the consequent development of a typical type B hepatitis
in the recipients. Recently, this aspect has been the focus of
several extensive reviews and articles and we refer to them for
an exhaustive discussion of the theme [50, 51, 66–68]. Here,
our scope is to stress some particular aspects that have rele-
vance in the general debate on OBI.
In the last 20 years, the risk of HBV infection after blood
transfusion has dramatically decreased due to the implemen-
tation of progressively more sensitive and specific diagnostic
tests. In fact, post-transfusional hepatitis B is, at present, a rare
event in the western world, although some residual cases still
occur [69]. Schematically, three conditions may be responsi-
ble for the transfusional transmission of HBV:
1. The donor is in the window period (the HBsAg-negative,
viremic, early acute phase of HBV infection). This is not
the subject of the present paper and, in any case, it
accounts for a minority of OBI-positive blood donors
[68].
2. The donor is a typical “OBI carrier” with a wild-type
virus which replication activity and gene expression are
suppressed. This point is important and intriguing, and
it should be taken into account that OBI infection is
characterized by periods of transient HBV viremia al-
ternating with periods in which the viral DNA is unde-
tectable in the serum [50, 70, 71]. Thus, an occult HBV-
infected individual may have a profile of blood infec-
tivity fluctuating over time. However, one important
point is the real ability of the very low amount of serum
HBV DNA usually present in OBI carriers to generate
acute hepatitis B in the recipient. It seems that HBV
DNA-positive donors with anti-HBc as the only sero-
logical marker are more infectious than those carrying
anti-HBs [68]. In an animal model of chimpanzees, the
minimum 50 % infectious dose (CID50) of HBV was
estimated to be approximately ten copies [72], whereas
in humans, it is far from being established [68], al-
though the possibility of inducing acute hepatitis is
likely dependent on the viral load, the amount of plasma
transfused, the immunocompetence of the recipient, and
the HBV serological status (presence/absence of anti-
HBc and/or anti-HBs) in both donor and recipient.
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Nevertheless, it should be considered that the lack of acute
hepatitis development does not exclude HBV transmis-
sion and infection of the recipient who, in turn, might
theoretically become occult HBV-infected.
3. The donor is infected with variant HBV strains (S-
escape mutants) that are replication-competent but pro-
duce abnormal surface proteins that are not recognized
by the commercially available HBsAg detection kits.
This condition appears to be a major cause of the
residual cases of HBV transmission by blood transfu-
sion. In this context, the use of multivalent anti-HBs
antibodies in the HBsAg detection kits has been recent-
ly recommended by an expert panel for the identifica-
tion of blood donors infected by HBsAg escape mutants
[2], even if this strategy does not definitely solve the
problem of post-transfusion HBV infection, especially
in geographic areas where HBV infection is highly
endemic and the viral genomic variability is potentially
the highest.
The introduction of Nucleic Acid Testing (NAT) for HBV
was intended to identify all blood donors with circulating
HBV DNA independently of each of the above reported
conditions. Actually, NAT for HBV has revealed that a
small part of HBsAg-negative blood donors worldwide have
detectable amount of HBV DNA in the serum. Although
data are not homogeneous due to the different population
examined (i.e., first or repeated blood donors, replacement
blood donors, or general population) and to the different
sensitivity of the assays used, what clearly emerged in the
studies based on the NAT technique is that the frequency of
HBV DNA detection in HBsAg-negative subjects varies
considerably according to the prevalence of the infection
in the different geographical areas. In addition, these studies
have shown that OBI and HBV S-escape mutant infections
may be identified in anti-HBc-positive samples (approxi-
mately 50 % of which also carrying anti-HBs) but also in
rare cases of anti-HBs without the presence of anti-HBc, as
has been described in vaccinated and nonvaccinated blood
donors [66, 73].
Organ transplantation
The HBV transmission from an OBI donor in the event of
OLT is a well known and frequent cause of de novo hepatitis
B in cases where the recipient is HBV naïve [20, 74]. This is
the obvious consequence of the fact that the hepatocytes are
the reservoir of HBV cccDNA (indeed occult HBV appears
to have very low rates of occurrence in cases of kidney,
heart, and bone marrow transplantation [20]) and it is the
basis for the general agreement in performing anti-HBV
prophylaxis (with hepatitis B immunoglobulin, lamivudine,
or their combination) in HBsAg-negative transplanted
patients who receive livers from anti-HBc positive donors
(of note, OBI transmission from HBV seronegative individ-
uals is uncertain and remains difficult to recognize). This
prophylaxis appears to be very effective in preventing de
novo HBV hepatitis in the recipients [75] but not to avoid
HBV reinfection [74]. In fact, several recent studies have
clearly demonstrated the frequent occurrence of OBI in
transplanted individuals who were occult-infected prior to
OLT and/or received the new organ from an OBI carrier. In
the “new” liver, HBV genomic sequences (and also HBV
cccDNA) are present and may derive from occult viruses
previously infecting the recipient, the donor, or even both
[76]. Whether OBI in these conditions might have any
clinical relevance in long-term outcome has to be clar-
ified, although some preliminary evidence suggests a
possible involvement in faster progression of post-transplant
liver disease in HCV-positive patients [77]. Of note,
OBI also develops in HBsAg-positive transplanted patients
who are treated with hepatitis B immunoglobulins and lam-
ivudine and become HBsAg-negative in the post-OLT period
[76].
OBI reactivation
The possible HBV reactivation in patients with diseases
involving the immune system or undergoing immuno- and/
or chemotherapy is a well-known phenomenon. This is a
field of growing interest also as a consequence of the avail-
ability of new, potent immunological drugs used in different
clinical contexts. HBV reactivates very frequently in HBsAg-
positive individuals undergoing immunosuppression, and this
event may occur also in OBI patients where it is often associ-
ated with the fulminant course of hepatitis [78]. Consequently,
HBV reactivation in immunocompromised patients has re-
cently been the focus not only of many studies but also of
meetings, reviews, and position papers [79–81]. Moreover, it
is an argument subject dealt with in all international guidelines
for the management of HBV infection published in the last
few years. Here, we briefly and schematically report the
aspects we consider preeminent in the field of viral reactivation
in OBI patients.
Thus, the strong suppression of viral replication and gene
expression typical of the occult HBV status may be discon-
tinued in patients under conditions of immunosuppression,
who may consequently have a reactivation of the viral
replication because of the drop in immunological control.
As mentioned above, this is very important, though
indirect, proof of the role played by immune control in induc-
ing OBI. Of note, however, recent reports indicate that also the
use of histone deacetylase inhibitors may be associated
with OBI reactivation [40, 82], confirming the involve-
ment of epigenetic mechanisms in the control of HBV
activities and, consequently, modifications of viral
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cccDNAminichromosome structure and dynamics as possible
causes of viral reactivation.
One main question is how frequent the viral reactivation
in OBI patients is. Surely, it occurs more rarely than in
HBsAg-positive cases, and it likely varies depending on
different clinical settings and therapeutic treatments (Table 2),
hematological malignancies, hematopoietic stem cell trans-
plantation, and treatments including rituximab conditions be-
ing at high risk [20, 83, 84]. In this context, we would like to
stress that OBI reactivation is usually diagnosed when it is
followed by the occurrence of acute hepatitis. However, there
is clear evidence that OBI individuals may frequently change
their HBV serological profile if immunocompromised: in fact,
anti-HBs positive individuals may lose this antibody during
immunosuppressive therapy and two distinct studies have
revealed that HBsAg re-seroconversion often occurs in sub-
jects undergoing hematopoietic stem cell transplantation, al-
though only a minority of these cases develop clinically
typical acute hepatitis [85, 86]. Consequently, one might
speculate that OBI reactivation is a quite frequent occurrence
in itself, but it is rarely followed by a clinically acute
event, thus its recognition and diagnosis might be missed in
many cases.
While prophylactic anti-HBV therapy with nucleos(t)ide
analogues (NA) is a well-consolidated practice for the pre-
vention of reactivation in HBsAg-positive patients undergo-
ing immunosuppressive therapies, the prophylactic antiviral
treatment in cases of patients suspected to be OBI-positive
(HBsAg-negative, anti-HBc +/− anti-HB-positive) is still an
argument of debate. The guidelines for the management of
CHB licensed by the EASL in 2009 recommended testing
these patients for HBV DNA and treating them as HBsAg-
positive subjects when viral DNA is detectable, whereas
when it is undetectable, they should be followed carefully
by means of ALT and HBV DNA testing and treated with
NA therapy upon confirmation of HBV reactivation before
ALT elevation [1]. The scope of this narrow surveillance is
clearly to recognize the viral reactivation in a phase ante-
ceding the beginning of liver injury to prevent hepatitis
development. In fact, once this event is established, the NA
treatment is not always effective probably due to the late start
of the antiviral therapy. Of note, some recent reports indicate
that the use of the most potent NA drugs may still make it
possible to efficaciously cure acute, severe hepatitis following
OBI reactivation [87, 88].
Occult HBV infection and chronic liver disease
A major and largely debated topic is whether occult HBV
may provoke (or contribute to) liver damage and in which
cases (or conditions) this event may occur or may be rele-
vant from a clinical point of view. In this context, it seems
important to consider that although individuals who recover
from self-limited acute hepatitis persistently carry HBV
genomes over time without showing any clinical or bio-
chemical sign of liver damage [20, 65] when the hepatic
tissue of such subjects was examined, histological patterns
of a mild necroinflammation were detected up to several
decades after the resolution of the acute hepatitis [89, 90].
These observations are in accordance with studies on the
woodchuck model showing that animals convalescing from
acute WHV hepatitis show lifelong persistence of small
amounts of replicating virus associated with mild liver nec-
roinflammation continuing for life [22]. Much evidence
indicates that OBI is associated with the most severe forms
of liver disease in HCV-infected patients, thus suggesting
that occult HBV might favor or accelerate the progression of
HCV-related CLD [5, 20]. Of note, recent reports have
shown an association between phases of a rise in ALT levels
and reappearance of circulating HBV DNA in patients with
chronic hepatitis C and combined OBI, thus suggesting an
active role of transient reactivation of HBV replication in
liver cell injury [70, 71]. Altogether these data seem to
confirm our previously reported hypothesis that, at least in
conditions of immune competence, the occult infection is
inoffensive in itself, but when other important causes of
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liver damage coexist (i.e., HCV infection, alcohol abuse,
etc.), the minimal lesions produced by the immune response
to the occult virus might contribute to making the course of
the liver disease worse over time [91].
As a note, it is correct to mention that several clinical
studies performed in the 1990s suggested that OBI may
negatively influence the response to IFN therapy in chronic
hepatitis C patients [5, 20]. Although the hypothesis that
OBI may help HCV to resist IFN is intriguing, it has to be
pointed out that all these studies concerned treatment sched-
ules using conventional IFN therapy, whereas whether oc-
cult HBV may interfere with the response to pegylated-IFN
plus ribavirin has not been adequately investigated so far. In
any case, one may imagine that the advent of direct antiviral
agents for the cure of HCV will likely make this topic flimsy
from a practical point of view.
On the basis of the above-mentioned hypothesis that
occult HBV might be unable to produce severe hepatic
injury by itself, it appears difficult to provide an explanation
to the considerable evidence indicating that OBI is associ-
ated with the progression of liver fibrosis and cirrhosis
development also in patients with cryptogenic liver disease
[5, 20]. Plausibly, a portion of these cases concerns individ-
uals with a previously productive HBV infection where a
progressive reduction of viral replication and serum HBsAg
amount occurs. The HBsAg may even disappear over time
despite the presence of severe liver disease that had been
provoked by the overt B hepatitis and then be maintained
once the occult HBV status develops. Of course, one cannot
exclude that unrecognized causes of hepatic injury might
concur with OBI to the induction of other cases of cryptogenic
CLD.
Occult HBV infection and HCC
A large body of evidence shows that HBV infection is the
main risk factor for HCC development and the World Health
Organization includes HBV in “group 1” human carcino-
gens, classifying it among the most important oncogenic
agents after tobacco smoking [16]. Furthermore, many epi-
demiological and molecular studies performed since the 80s
indicate almost unanimously that HBV persistence may play
a critical role in the development of HCC also when the
occult status of the infection occurs [16, 92]. This evidence
is validated by a recent meta-analysis evaluating the studies
focusing on this topic and confirming that OBI is an important
risk factor for HCC development both in HCV-infected and
HCV-negative patients with CLD [93]. Among HCV-negative
patients, OBI appears able to exert its pro-oncogenic role in
individuals without known causes of liver damage as well as
in alcoholics and individuals with virus unrelated liver pathol-
ogies [20, 23, 94]. In this context, of great importance is a
recent population-based cohort study conducted for more than
two decades on Taiwanese mothers screened for HBV infec-
tion at each delivery and demonstrating that the risk of HCC
development was significantly higher in women with persis-
tent HBsAg-positive status, but among the HBsAg-negative
mothers, those who underwent HBsAg sero-clearance during
follow-up had a significantly higher risk of HCC development
compared to HBV-unexposed women. In fact, this study
indicates that HBV maintains its pro-oncogenic role also in
the occult status and even in women that are known to be
much less prone to develop liver cancer thanmen [95]. Finally,
experiments in animal models showed that both woodchucks
and ground squirrels, once infected by the corresponding hep-
adnaviruses, are at high risk of developing HCC also after the
apparent clearance of the virus with disappearance of the viral
surface antigen and seroconversion to the corresponding
antibody [16].
Complex and multifactorial pathogenetic mechanisms
underlie HCC development and much evidence reveals that
HBV is involved in many of these mechanisms. In particular,
chronic HBV infection is believed to exert its pro-oncogenic
properties through both indirect and direct mechanisms: the
indirect mechanisms are related to its propensity to induce
continuous or recurrent phases of liver necroinflammation and
to promote the progression of chronic hepatitis to cirrhosis
(which is the step preceding the development of HCC in the
vast majority of the cases); the direct carcinogenic mecha-
nisms have been related to the ability of HBV to integrate into
the host’s genome and to produce proteins, mainly X protein
and truncated preS-S protein, provided with potential trans-
forming properties. Considering that in OBI status (a) HBV
DNA can persist in the hepatocytes both integrated into the
host genome and as free episome; (b) the virus maintains its
replication and transcriptional activity and ability to synthe-
size proteins, albeit at very low levels; and (c) the occult virus
may determine a mild but continuous status of chronic nec-
roinflammation and might contribute to progression toward
cirrhosis, it is generally believed that OBI can contribute to
hepatocellular transformation through the same direct and
indirect mechanisms that subtend HCC development in overt
HBV infection.
Other tumors where OBI involvement
has been hypothesized
Recent data indicate an association between HBV infection
and malignancies other than HCC, such as intrahepatic
cholangiocarcinoma and non-Hodgkin lymphoma [96–98].
Some evidence also suggests a possible involvement of OBI
in these conditions [99, 100]. The tumorigenic mechanisms
exerted by HBV in both these conditions need be totally
elucidated, although the origin from the same progenitor
cells of hepatocytes and cholangiocytes, on one hand, and
the supposed lymphotropism of HBV, on the other hand,
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provide some theoretical basis for this intriguing topic. Of
course, large cohort studies must be performed to verify
these data firstly in HBV infection and, subsequently, in
cases of OBI.
Summary and conclusions
The availability of highly sensitive molecular biology tech-
niques made it possible to disclose several virological
aspects of OBI, to show its worldwide diffusion, and to
reveal its possible implication in various clinical contexts.
It appears well established that the molecular basis of OBI is
related to the long-term persistence of HBV cccDNA in the
nuclei of the hepatocytes, and OBI can be considered as a
phase in the natural history of chronic HBV infection. The
mechanisms determining OBI status have still to be mostly
elucidated, but it is evident that viral factors (i.e., HBV
genetic heterogeneity) have no relevant role in the majority
of cases, while host factors appear to play an essential role
by suppressing the viral activities. These biological aspects
have clinical repercussions, since environmental changes
leading to the breakdown of the host–virus balance may
determine the reactivation of the virus replication ability
and the development of a “typical” hepatitis B. This event
may occur when the immunological status of an OBI patient
is modified as in cases undergoing immunosuppressive
therapies but also when drugs able to interfere with the
epigenetic control of the HBV replication are used. In anal-
ogy, because of their replication competence, when occult
viruses are transmitted to other individuals, they may induce
hepatitis B. In fact, OBI is responsible for the large majority
of the residual cases of transfusion-transmitted HBV hepa-
titis that is a rare event in the most developed countries but
is still a quite serious problem in areas where the high HBV
endemicity and the elevated costs of NAT diagnostic
approaches hamper a totally efficient check of all transfu-
sion blood units. HBV may be also transmitted in cases of
OLT from an OBI-positive donor. In these cases, the event
of de novo hepatitis B is, at present, prevented by the use of
anti-HBV prophylaxis in the recipient. A widely debated
aspect concerns the possible involvement of OBI in the
progression toward cirrhosis of patients with chronic hepa-
titis. In this context, one should consider that OBI is a
complex entity which includes several clinical/virological
conditions quite different from one another such as, (a)
patients rapidly recovered from self-limited hepatitis, (b)
patients who had overt CHB for years or decades before
losing the HBsAg, and (c) HBV seronegative patients, most
of whom had likely been infected with minute amounts of
viruses insufficient to induce a strong, specific immune
response. One cannot rule out the possibility that these
conditions may have a different impact on the outcome of
the liver disease, and studies aiming at investigating this
important feature must be performed in the near future. Final-
ly, OBI appears to maintain most of the pro-oncogenic prop-
erties usually attributed to the overt HBV infection and quite
solid evidence indicates that it is a risk factor for HCC devel-
opment. However, several aspects still need to be elucidated,
such as the epidemiology of OBI-associated HCCs. More-
over, molecular studies addressed at analyzing liver samples
from large series of OBI-associated HCC compared to both
overt HBV-associated HCC and HBV-negative HCC are still
lacking. OBI is a fascinating field of viral hepatitis research
and learning about it is fundamental for an overall understand-
ing of HBV infection. One main issue that OBI studies have
contributed to provide is that HBV, once infection occurs, is
not eradicable even by the use of the most potent anti-HBV
drugs at present available. Thus, the only chance to really win
the war against this terrible (and “smart”) enemy of human
health is to extend neonatal vaccination to all the countries,
particularly where the virus is endemic.
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